Ugur Sahin, AP Images
Covid-19 roundup: BioNTech prepares for vaccine launch in 5- to 11-year-olds; Sinovac weighs vaccine production site in South Africa — report
As children return to school and youth Covid-19 hospitalizations hit a new high, BioNTech is reportedly prepping a launch for its mRNA vaccine developed with Pfizer in those between 5 and 11 years old.
BioNTech CMO Özlem Türeci told the weekly German magazine Der Spiegel that the company will file the results of its trial in 5- to 11-year-olds with regulators across the world “over the next few weeks,” and that final production steps are being adjusted to bottle a lower-dose pediatric version of the vaccine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
